P/OSPeptideOS evidence & status map
OPEN SOURCE MEDICINE FOUNDATIONLast reviewed 2026-10-10No dosing · no vendors · no advicesource file

← All compounds · evidence tier first, by design

Evidence tier for each claimed use · ← established · unknown →
UseE1E2E3E4E5E6E7E8
E1 Type 2 diabetes: glycaemic control and cardiovascular outcomesE1
E1 Chronic weight management (obesity or overweight)E1
E1 Obstructive sleep apnoea with obesityE1
E2 Heart failure with preserved ejection fraction and obesityE2
E3 Metabolic dysfunction-associated steatohepatitis (MASH)E3
Class A · Approved

Tirzepatide

Synthetic peptide containing non-coded amino acids and a fatty diacid side chain; not representable as a plain one-letter sequence.

Non-standard residues or modifications: no plain one-letter sequence

Codes: LY3298176 · Brands: Mounjaro, Zepbound · CAS 2023788-19-2

A synthetic peptide that activates the receptors for two gut hormones, GIP and GLP-1. It is an approved prescription medicine for type 2 diabetes (Mounjaro) and for chronic weight management (Zepbound in the US and Japan; Mounjaro carries the weight indication in the UK). The UK MHRA has reported falsified Mounjaro pens in circulation. Status in China was not verified for this record.

  • US A approved
  • EU A approved
  • UK A approved
  • CA A approved
  • AU A approved
  • JP A approved
  • CN ? not verified

01Regulatory status, by jurisdiction

JurisdictionStatusDetail and primary source
USApprovedDrugs@FDA NDA 215866 (Mounjaro, Eli Lilly), original approval 05/13/2022 as a new molecular entity. Zepbound is NDA 217806 (approved 11/08/2023).
“05/13/2022 ORIG-1 Approval Type 1 - New Molecular Entity PRIORITY”
Drugs@FDA: FDA-Approved Drugs, NDA 215866 · retrieved 2026-10-10
EUApprovedCentrally authorised as Mounjaro on 15 September 2022.
“Mounjaro received a marketing authorisation valid throughout the EU on 15 September 2022.”
Mounjaro | European Medicines Agency (EPAR) · retrieved 2026-10-10
UKApprovedMHRA press release of 8 November 2023 authorising a weight-management indication for Mounjaro, which it describes as already used for type 2 diabetes.
“The Medicines and Healthcare products Regulatory Agency (MHRA) has today (8 November 2023) authorised via a national application route, a new indication for the diabetes medicine, Mounjaro (tirzepatide), for weight loss and weight management in adults aged 18 and over.”
MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss · retrieved 2026-10-10
CAApprovedHealth Canada Drug Product Database, Mounjaro (drug code 102190), status Approved, 2022-11-24.
“"drug_code":102190,"status":"Approved","history_date":"2022-11-24"”
Health Canada Drug Product Database API: status, drug code 102190 (Mounjaro) · retrieved 2026-10-10
AUApprovedTGA Product Information repository lists a PI for Mounjaro (tirzepatide). The main TGA ARTG search (tga.gov.au) timed out on retrieval.
“Search PI Trade Names and Active Ingredients containing tirzepatide . 1 Documents available.”
TGA eBS - Product and Consumer Medicine Information (search: tirzepatide) · retrieved 2026-10-10
JPApprovedPMDA List of Approved Products (New Drugs): Mounjaro approved Sep. 26, 2022 as a new active ingredient for type 2 diabetes; Zepbound approved Dec. 27, 2024 for obesity (restricted to patients with hypertension, dyslipidaemia or type 2 diabetes meeting BMI criteria).
“Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus.”
PMDA List of Approved Products: New Drugs (April 2004 to February 2026) · retrieved 2026-10-10
CNNot yet verified from a primary source. No status is shown rather than an unsourced one.

Sport (WADA): Not prohibited. Not named on the Prohibited List. As an approved medicine it also falls outside class S0, which covers only substances without current regulatory approval: “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development” WADA source

02What the human evidence shows

E1

Type 2 diabetes: glycaemic control and cardiovascular outcomes

n/cpublished human RCTs
n/cpublished human trials
70registered studies
28with posted results

n/c: not counted here; see the cited review.

Supported by the phase 3 SURPASS programme. In SURPASS-2 (1,879 participants on metformin), all tirzepatide doses lowered HbA1c more than semaglutide (differences -0.15 to -0.45 percentage points). In SURPASS-CVOT (13,299 participants with atherosclerotic cardiovascular disease), tirzepatide was non-inferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%, hazard ratio 0.92); superiority was not shown.

  • [1] HbA1c reduction superior to semaglutide at all three tirzepatide doses in type 2 diabetes on metformin
  • [2] Major cardiovascular events 12.2% vs 13.1% with dulaglutide (HR 0.92; non-inferior, not superior)

Registered-study counts: ClinicalTrials.gov intervention search “tirzepatide AND type 2 diabetes”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E1

Chronic weight management (obesity or overweight)

n/cpublished human RCTs
n/cpublished human trials
182registered studies
14with posted results

n/c: not counted here; see the cited review.

Multiple large randomised trials (SURMOUNT programme). In SURMOUNT-1 (2,539 adults without diabetes), mean weight change at week 72 ranged from -15.0% to -20.9% across dose groups versus -3.1% with placebo. In SURMOUNT-5 (751 adults without diabetes), weight change at week 72 was -20.2% with tirzepatide versus -13.7% with semaglutide. Gastrointestinal events were the most common adverse events in SURMOUNT-5.

  • [3] Mean weight change -15.0% to -20.9% vs -3.1% with placebo at week 72
  • [4] Weight change -20.2% vs -13.7% with semaglutide at week 72 in adults with obesity without diabetes

Registered-study counts: ClinicalTrials.gov intervention search “tirzepatide AND obesity”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E1

Obstructive sleep apnoea with obesity

n/cpublished human RCTs
n/cpublished human trials
6registered studies
1with posted results

n/c: not counted here; see the cited review.

Two randomised placebo-controlled phase 3 trials reported together (SURMOUNT-OSA, 469 participants). The apnoea-hypopnoea index fell by 25.3 and 29.3 events per hour with tirzepatide versus 5.3 and 5.5 with placebo at week 52 (treatment differences about -20 and -24 events per hour).

  • [5] AHI reduced by about 20-24 more events per hour than placebo at week 52 in two trials

Registered-study counts: ClinicalTrials.gov intervention search “tirzepatide AND sleep apnea”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E2

Heart failure with preserved ejection fraction and obesity

n/cpublished human RCTs
n/cpublished human trials
9registered studies
1with posted results

n/c: not counted here; see the cited review.

One phase 3 trial (SUMMIT, 731 patients, median follow-up 104 weeks). Cardiovascular death or worsening heart failure occurred in 9.9% with tirzepatide versus 15.3% with placebo (hazard ratio 0.62). The difference was driven by worsening heart-failure events; cardiovascular deaths were few (8 vs 5) and did not differ.

  • [6] Composite of cardiovascular death or worsening heart failure 9.9% vs 15.3% (HR 0.62)

Registered-study counts: ClinicalTrials.gov intervention search “tirzepatide AND heart failure”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E3

Metabolic dysfunction-associated steatohepatitis (MASH)

n/cpublished human RCTs
n/cpublished human trials
8registered studies
1with posted results

n/c: not counted here; see the cited review.

One phase 2 trial (SYNERGY-NASH, 190 participants, 157 with evaluable week 52 biopsies). MASH resolution without worsening fibrosis occurred in 44% to 62% across tirzepatide dose groups versus 10% with placebo. No phase 3 histology or liver-outcomes result has been published.

  • [7] MASH resolution 44-62% vs 10% with placebo at week 52 (phase 2)

Registered-study counts: ClinicalTrials.gov intervention search “tirzepatide AND steatohepatitis”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

Key registered trials

NCTTitle (as registered)PhaseStatus
NCT03987919A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes3Completed
NCT04255433A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes3Completed
NCT04184622A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight3Completed
NCT05822830A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities3Completed
NCT04847557A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial3Completed
NCT04166773A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)2Completed

03Safety signals

S1Large long-term human exposure (post-marketing surveillance)
  • Gastrointestinal adverse events [2]
    Gastrointestinal events were the most common adverse events in SURMOUNT-5, mostly mild to moderate. SURPASS-CVOT reported more gastrointestinal adverse events with tirzepatide than dulaglutide. The UK MHRA strengthened warnings on acute pancreatitis for GLP-1 and dual GIP/GLP-1 receptor agonists in January 2026.
  • Gallbladder and biliary disease (incretin-class signal) [8]
    Meta-analysis of GLP-1 receptor agonist trials found increased gallbladder or biliary disease (RR 1.37); tirzepatide was not part of that analysis, so the class finding is indirect for this compound.
  • Thyroid C-cell tumours in rodents (GLP-1 receptor agonist class) [9]
    GLP-1 receptor agonists cause thyroid C-cell proliferation in rodents; human relevance is not established.

04What is unknown

  • Effect on cardiovascular death and hard outcomes in obesity without diabetes; no placebo-controlled outcome trial in that population has reported in a publication located for this record
  • Whether MASH histology improvements seen in a 190-participant phase 2 trial translate into fewer cirrhosis or liver-related events
  • Safety beyond the roughly two to three years covered by published randomised trials, including long-term gallbladder, pancreatic and thyroid outcomes
  • Separate contribution of GIP receptor agonism versus GLP-1 receptor agonism to the effects seen in humans
  • Content and purity of compounded or unlicensed tirzepatide products; falsified pens have been reported by the MHRA but systematic assay data are lacking

05Product quality

No independent purity results have been published for this compound yet. The purity programme will publish full methods and vendor-named results, passes and failures, once its protocol has had legal review.

06Citations

  1. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021). doi:10.1056/NEJMoa2107519
  2. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (2025). doi:10.1056/nejmoa2505928
  3. Tirzepatide Once Weekly for the Treatment of Obesity (2022). doi:10.1056/NEJMoa2206038
  4. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (2025). doi:10.1056/NEJMoa2416394
  5. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (2024). doi:10.1056/NEJMoa2404881
  6. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (2025). doi:10.1056/NEJMoa2410027
  7. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis (2024). doi:10.1056/NEJMoa2401943
  8. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. doi:10.1001/jamainternmed.2022.0338
  9. Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation. doi:10.1210/en.2009-1272

Every DOI is resolved against Crossref and every NCT number against ClinicalTrials.gov, title for title, before publication. Regulatory sources are cited inline above with a verbatim quote and retrieval date.

07Mechanism

Tirzepatide is a single peptide that acts as an agonist at both the GIP and GLP-1 receptors. A fatty-acid side chain binds albumin and prolongs its duration of action.

Mechanism is placed last on purpose: a plausible mechanism is not evidence that a compound works in people.

Reviewed by OSMF research team (AI-assisted, source-verified) on 2026-10-10. Found an error? It goes in the corrections log: report it.